ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS (NCT06733922)
Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS)
🩺 Plain-English Summary (8th-Grade Level)
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Calgary, Alberta
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Novartis Investigative Site — Calgary, Alberta
- Novartis Investigative Site — Calgary, Alberta
- Novartis Investigative Site — Edmonton, Alberta
- Novartis Investigative Site — Burnaby, British Columbia
- Novartis Investigative Site — Vancouver, British Columbia
- Novartis Investigative Site — St. John's, Newfoundland and Labrador
- Novartis Investigative Site — Halifax, Nova Scotia
- Novartis Investigative Site — Halifax, Nova Scotia
- Novartis Investigative Site — Ottawa, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Québec, Quebec
- Novartis Investigative Site — Sherbrooke, Quebec
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsing Remitting Multiple Sclerosis (RRMS)
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" — Sugar Land, Texas
Explore by condition: All Relapsing Remitting Multiple Sclerosis (RRMS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.